 |
INVESTOR RELATIONSTHE INFORMATION IN THIS SECTION IS BEING DISCLOSED FOR THE PURPOSES OF RULE 26 OF THE AIM RULES FOR COMPANIES.
INFORMATION ON THIS SECTION OF THE WEBSITE WAS LAST UPDATED ON 22 DECEMBER 2010.
Introduction
Omega Diagnostics Group PLC was established in September 2006 when Omega Diagnostics Limited completed a “reverse acquisition” of an AIM Listed Cash Shell Company called Quintessentially English PLC. In September 2007, the Group completed the acquisition of Genesis Diagnostics Ltd and Cambridge Nutritional Sciences Ltd.
Omega sells a wide range of immunoassay-based products in the in-vitro diagnostics (IVD) market, through a strong distribution network in over 100 countries.
Omega operates in niche markets, supplying tests based on agglutination, enzyme immunoassay (EIA), fluorescence, rapid and microarray technologies. Omega specialises in the diagnosis of infectious diseases including Syphilis, TB, Dengue Fever, Chagas Disease and Malaria. Omega has recently added food intolerance and autoimmune tests for diseases such as anaemia, connective tissue disease and renal disease.
All products are designed for use in Clinical Laboratories and Rapid Tests are designed for use at the point of care.
Omega’s export success was officially recognised with the Queen’s Award for Export Achievement in 1993.
|
Directors |
|
|
David Evans, CA, Non-Executive Chairman
Andrew Shepherd, BSc.(Hons.), Chief Executive
Kieron Harbinson, FCCA, Finance Director
Michael Gurner, FCA, Non-Executive Director
Geoff Gower, BSc. (Hons), Managing Director
|
|
Corporate governance and internal controls
|
|
|
For further information please click on the PDF links to the Admission Documents below.
|
 |
 |
 |
|
|
Country of Incorporation Omega Diagnostics Group PLC
England & Wales
Registered No. 5017761
Registered Office Omega Diagnostics Group PLC
One London Wall,
London EC2Y 5AB
Country of Incorporation Omega Diagnostics Limited
Scotland
Registered No. 107178
Registered Office Omega Diagnostics Limited
Omega House, Hillfoots Business Village, Alva
Clackmannanshire, FK12 5DQ
|
Main Country of Operation
Scotland |
|
|
VAT Registration No.
GB735 0741 45
Details of Exchanges/Trading Platforms
AIM
|
|
Annual Reports/Interim Results |
|
|
|
Link to the London Stock Exchange (LSE) |
|
|
|
RNS Announcements |
|
The last five announcements can be viewed on the LSE:ODX website link.
The complete announcement history can be viewed via the following link:-
|
|
Shareholding as at 4 JULY 2011 |
|
The number of shares in issue is 85,216,257.
The percentage of shares not in public hands at
4 July 2011 is 52.54%.
|
Significant Shareholders |
|
|
|
|
|
|
|
Legal & General Investment Management |
15,300,000 |
17.95% |
|
|
Matrix Income Funds |
12,499,900 |
14.67% |
|
|
Octopus Investments
Brewin Dolphin Securities |
11,196,870
5,236,502 |
13.14%
6.14% |
|
|
Unicorn Asset Management |
4,266,650 |
5.01% |
|
|
Williams de Broe |
4,118,601 |
4.83% |
|
|
JM Finn & Co |
3,821,000 |
4.48% |
|
|
David Evans |
2,870,134 |
3.37% |
|
|
Hargreave Hale |
2,836,244 |
3.33% |
Details of restrictions on the transfer of shares
|
|
Articles of Association |
|
|
|
|
|
|
Nominated Advisor/Brokers |
|
|
Cenkos Securities plc
6.7.8 Tokenhouse Yard
London EC2R 7AS |
|
|
|
|
|
|
Auditors |
|
|
Ernst & Young LLP
Ten George Street
Edinburgh EH2 2DZ
|
|
Solicitors |
|
Brodies LLP
15 Atholl Crescent
Edinburgh EH3 8HA
|
|
Share Registrar |
|
Share Registrars Limited
Suite E
First Floor, 9 Lion and Lamb Yard
Farnham
Surrey GU9 7LL
|
|
PR |
|
|
Walbrook PR Ltd
4 Lombard Street
London EC3V 9HD
|
|
